491 related articles for article (PubMed ID: 10962353)
1. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL.
Neale SD; Smith R; Wass JA; Athanasou NA
Bone; 2000 Sep; 27(3):409-16. PubMed ID: 10962353
[TBL] [Abstract][Full Text] [Related]
2. Gender- and age-related differences in osteoclast formation from circulating precursors.
Jevon M; Sabokbar A; Fujikawa Y; Hirayama T; Neale SD; Wass J; Athanasou NA
J Endocrinol; 2002 Mar; 172(3):673-81. PubMed ID: 11874715
[TBL] [Abstract][Full Text] [Related]
3. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis.
Hirayama T; Danks L; Sabokbar A; Athanasou NA
Rheumatology (Oxford); 2002 Nov; 41(11):1232-9. PubMed ID: 12421995
[TBL] [Abstract][Full Text] [Related]
4. The influence of serum cytokines and growth factors on osteoclast formation in Paget's disease.
Neale SD; Schulze E; Smith R; Athanasou NA
QJM; 2002 Apr; 95(4):233-40. PubMed ID: 11937650
[TBL] [Abstract][Full Text] [Related]
5. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA
J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498
[TBL] [Abstract][Full Text] [Related]
6. Isolation of human osteoclasts formed in vitro: hormonal effects on the bone-resorbing activity of human osteoclasts.
Kudo O; Sabokbar A; Pocock A; Itonaga I; Athanasou NA
Calcif Tissue Int; 2002 Dec; 71(6):539-46. PubMed ID: 12232680
[TBL] [Abstract][Full Text] [Related]
7. Cellular and humoral mechanisms of osteoclast formation and bone resorption in Gorham-Stout disease.
Hirayama T; Sabokbar A; Itonaga I; Watt-Smith S; Athanasou NA
J Pathol; 2001 Dec; 195(5):624-30. PubMed ID: 11745700
[TBL] [Abstract][Full Text] [Related]
8. 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease.
Menaa C; Barsony J; Reddy SV; Cornish J; Cundy T; Roodman GD
J Bone Miner Res; 2000 Feb; 15(2):228-36. PubMed ID: 10703924
[TBL] [Abstract][Full Text] [Related]
9. The generation of highly enriched osteoclast-lineage cell populations.
Quinn JM; Whitty GA; Byrne RJ; Gillespie MT; Hamilton JA
Bone; 2002 Jan; 30(1):164-70. PubMed ID: 11792580
[TBL] [Abstract][Full Text] [Related]
10. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
11. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis.
Tsurukai T; Udagawa N; Matsuzaki K; Takahashi N; Suda T
J Bone Miner Metab; 2000; 18(4):177-84. PubMed ID: 10874596
[TBL] [Abstract][Full Text] [Related]
12. Cellular mechanisms of bone resorption in breast carcinoma.
Hunt NC; Fujikawa Y; Sabokbar A; Itonaga I; Harris A; Athanasou NA
Br J Cancer; 2001 Jul; 85(1):78-84. PubMed ID: 11437406
[TBL] [Abstract][Full Text] [Related]
13. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
14. Osteoclast formation from circulating precursors in osteoporosis.
Jevon M; Hirayama T; Brown MA; Wass JA; Sabokbar A; Ostelere S; Athenasou NA
Scand J Rheumatol; 2003; 32(2):95-100. PubMed ID: 12737328
[TBL] [Abstract][Full Text] [Related]
15. Cell biology of Paget's disease.
Reddy SV; Menaa C; Singer FR; Demulder A; Roodman GD
J Bone Miner Res; 1999 Oct; 14 Suppl 2():3-8. PubMed ID: 10510206
[TBL] [Abstract][Full Text] [Related]
16. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages.
Itonaga I; Sabokbar A; Murray DW; Athanasou NA
Ann Rheum Dis; 2000 Jan; 59(1):26-31. PubMed ID: 10627423
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
Nagata N; Kitaura H; Yoshida N; Nakayama K
Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
[TBL] [Abstract][Full Text] [Related]
18. The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6, and -11, tumor necrosis factor-alpha, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells.
Fujikawa Y; Sabokbar A; Neale SD; Itonaga I; Torisu T; Athanasou NA
Bone; 2001 Mar; 28(3):261-7. PubMed ID: 11248655
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL
J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
